|
|
An Open Letter To Congressman Holt
on Severe, Disabling Reactions Linked to Cipro, Levaquin, and Other
Fluoroquinolone Antibiotics.
Dear Congressman
Holt, Thank you for taking the time to
speak with people concerned about, or injured from, reactions associated
with fluoroquinolone antibiotics (e.g. Levaquin, Cipro, Floxin, Tequin). I
am the author of a study about severe, long-term fluoroquinolone reactions
published in the December 2001 issue of the Annals of
Pharmacotherapy.1 Actually, the publisher and
I pre-released this article in October 2001, during the anthrax scare when
Cipro was being prescribed indiscriminately and without warnings to
patients. Within days of publication of my paper, the U.S. Centers for
Disease Control changed their guidelines, placing the antibiotics
doxycycline and penicillin above Cipro as the preferred treatments for
anthrax exposure. Doxycycline and penicillin are associated with fewer
severe side effects than fluoroquinolones, and they are not linked with
the devastating, disabling, long-term reactions that my study
identified. These severe reactions are
occurring in patients who are usually healthy, active, and young. Most
often, the antibiotics are prescribed for mild infections such as
sinusitis, urinary or prostate infections. Most reactions occur very
quickly, sometimes with just a few doses of the fluoroquinolone
antibiotic. Reactions are acute, severe, frightening, and often disabling.
In most cases, side effects are multiple, involving many systems of the
body. In my study, nervous system symptoms occurred in 91% of patients,
musculoskeletal 73%, sensory system 42%, cardiovascular 36%, skin 29%,
gastrointestinal 18%. These numbers do
not adequately capture the severity and permanence of these reactions.
Here are some examples:
Male, age 36, previously
in good health, received Cipro for possible urinary infection: Chronic,
debilitating multi-focal neuropathy, fibromyalgia, chronic fatigue,
gastrointestinal problems, heart arrhythmia requiring pacemaker, carpal
tunnel syndrome, chronic multiple joint pains, chronic pain. Functional
ability: disabled. Duration: 5 years (patient now age
41).
Female, age 32, previously in good health, received Cipro
for urinary infection: After 5 days, developed pain in wrists, neck,
back, knees, hips, elbows, shoulders, and Achilles tendons. Having
difficulty writing. Medical workup normal. Functional ability: greatly
limited.
Female: age 47, previously in good health, received
Levaquin for sinusitis: Within 2 days developed joint pain (severe in
hands), insomnia, severe agitation, weakness, dizziness, severe fatigue,
mental infusion, abnormal dreams, gastrointestinal symptoms. Duration:
Still severe after 7 months.
Female, age 49, previously in good
health, received Floxin for a pelvic infection: Burning pain, memory
loss, joint pains, palpitations, nerve pain, insomnia, abnormal sense of
smell, tinnitis, panic attacks. Duration: more than 3
years.
Male, age 34, previously in good health, received Levaquin
for prostate infection: Muscle spasms and twitching, numbness, impaired
coordination, weakness, increased sensitivity to temperatures, fatigue,
multiple joint, muscle pain, palpitations, blurred vision. Duration:
more than 1 year.
Male, age 35, in good health, received Levaquin
for prostate infection: 1 dose was followed by ringing in the ears and
peripheral nerve symptoms lasting 2 weeks. Then tendonitis began in
shoulders, elbows, wrists, hands, and Achilles tendons, with burning
pain and tightness in calves. After 2 months, still unable to walk more
than a short distance. This man told me, "Prior to taking the medication
I asked about side effects and was told there were none for adults
except an upset stomach. Afterwards I was told that what I was
experiencing could not be related to the drug. Obviously the doctor had
never read the documentation that states
otherwise."
These are not isolated
cases. Since the publication of my article with its 45 cases two and a
half years ago, I have received e-mails from more than 100 people seeking
help for their reactions. In most cases, their doctors have dismissed
their complaints or outright deny that the reactions could occur with
fluoroquinolones. Yet extensive medical workups do not find any other
cause. Worse, there are no known effective treatments. Thus, these people
suffer pain and disability for weeks, months,
years. Overall, my sense is that these
reactions are not rare. I have spoken to the U.S. Food and Drug
Administration about this. I am shocked that the agency still hasn't
acted. Other major reactions such as Stevens-Johnson syndrome or Churg
Strauss syndrome from medications are posted prominently on drug labels.
These reactions are much rarer than the ones occurring with
fluoroquinolone antibiotics. At the very least, black boxes should be
placed in fluoroquinolone package inserts about severe, multi- system
reactions. I readily agree that
fluoroquinolone antibiotics play an important role in treating infections
diseases, but we must alert doctors and patients about the potential
devastating effects linked to these drugs. We must educate them that if
any signs of reactions occur, such signs should be reported immediately
and the drugs should be discontinued. Patients have a right of informed
consent, and this includes warnings of potential serious, disabling
reactions. Most of all, we must educate doctors to avoid prescribing
fluoroquinolones for minor infections, instead saving them for serious
infections, just as we do with other groups of antibiotics with serious
toxicities. I hope you will look
seriously at this problem and respond accordingly. These people need your
help. This is a largely preventable problem. Thank you.
Jay S.
Cohen, M.D. Associate Professor (voluntary) Departments of Family
and Preventive Medicine and of Psychiatry University of California, San
Diego
President and Executive Director The Center for the
Prevention of Medication Side Effects A Nonprofit, Tax-Exempt
[501(C)(3)] Corporation
For more information on this
subject, please see: Reactions
to Cipro, Levaquin, and Other Fluoroquinolone Antibiotics in the
July-Sept E-Newsletter.
REFERENCE: 1. Cohen, JS.
Peripheral Neuropathy with Fluoroquinolone Antibiotics. Annals of
Pharmacotherapy, Dec. 2001;35(12):1540-47.
Copyright 2004, Jay S. Cohen, M.D. All rights reserved. Readers have
permission to copy and disseminate all or part of these articles if it is
clearly identified as the work of: Jay S. Cohen, M.D., the MedicationSense
E-Newsletter, www.MedicationSense.com. You may not use this work for
commercial purposes.
If you find this
article informative, please tell your friends, family members, colleagues,
and doctors about www.MedicationSense.com and the free MedicationSense
E-Newsletter.
NOTE TO
READERS: The purpose of this E-Letter is solely
informational and educational. The information herein should not be
considered to be a substitute for the direct medical advice of your
doctor, nor is it meant to encourage the diagnosis or treatment of any
illness, disease, or other medical problem by laypersons. If you are under
a physician's care for any condition, he or she can advise you whether the
information in this E-Letter is suitable for you. Readers should not make
any changes in drugs, doses, or any other aspects of their medical
treatment unless specifically directed to do so by their own
doctors.
Copyright 2004, Jay S. Cohen, M.D. All rights
reserved.
Site
created and managed by Warwick Graphics. If
you notice any problems with this site please notify webmaster by clicking
here. |
|
|